Dr. Tolba on Targeting NRG1 Fusions With Afatinib
September 25th 2019
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the potential to target NRG1 fusion–positive lung adenocarcinoma with afatinib (Gilotrif).